Here are the 424B prospectus supplements from Insight Molecular Diagnostics Inc. (IMDX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IMDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMDX filings page.
Insight Molecular Diagnostics Inc. is conducting a primary offering of 3,482,498 shares of common stock and pre-funded warrants to purchase up to 1,043,478 additional shares of common stock. The shares are priced at $5.75 each and the pre-funded warrants at $5.7499, for gross proceeds of $26,024,257.65. Net proceeds are expected to be approximately $24.5 million after placement fees and expenses. The company plans to use the cash mainly for general corporate purposes and research and development in transplantation, including expanding its GraftAssure transplant rejection testing from kidneys into other organs, most immediately heart. Assuming full exercise of the pre-funded warrants, shares outstanding would be 33,151,381, and the transaction increases net tangible book value from $(0.83) to $0.02 per share, implying dilution of $5.73 per share to new investors.